Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Research & Development (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Research & Development data on record, last reported at $75.3 million in Q4 2025.

  • For Q4 2025, Research & Development rose 60.49% year-over-year to $75.3 million; the TTM value through Dec 2025 reached $245.1 million, up 49.85%, while the annual FY2025 figure was $245.1 million, 49.85% up from the prior year.
  • Research & Development reached $75.3 million in Q4 2025 per CLDX's latest filing, up from $62.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $75.3 million in Q4 2025 and bottomed at $12.4 million in Q2 2021.
  • Average Research & Development over 5 years is $33.1 million, with a median of $28.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: grew 8.76% in 2021, then soared 67.78% in 2022.
  • A 5-year view of Research & Development shows it stood at $14.7 million in 2021, then surged by 56.01% to $22.9 million in 2022, then soared by 32.87% to $30.4 million in 2023, then soared by 54.27% to $46.9 million in 2024, then skyrocketed by 60.49% to $75.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $75.3 million in Q4 2025, $62.9 million in Q3 2025, and $54.2 million in Q2 2025.